James Reuben

Professor

The University of Texas MD Anderson Cancer Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Supplementary Figure 7. T-cell activation observed as changes in peripheral blood T-cell receptor repertoire after 2 courses of pembrolizumab maintenance therapy. The boxplot shows the interquartile range with whiskers extending up to 1.5 times the interquartile range.

Year:

2024

Supplementary Figure 7. T-cell activation observed as changes in peripheral blood T-cell receptor repertoire after 2 courses of pembrolizumab maintenance therapy. The boxplot shows the interquartile range with whiskers extending up to 1.5 times the interquartile range.

Year:

2024

Supplementary Figure 5. Significant decreases in T-cell exhaustion markers were associated only with patients who responded to pembrolizumab maintenance therapy. The boxplot shows the interquartile range with whiskers extending up to 1.5 times the interquartile range

Year:

2024

Supplementary Figure 5. Significant decreases in T-cell exhaustion markers were associated only with patients who responded to pembrolizumab maintenance therapy. The boxplot shows the interquartile range with whiskers extending up to 1.5 times the interquartile range

Year:

2024

Purpose: Accumulating toxicities hinder indefinite chemotherapy for many patients with metastatic/recurrent HER2-negative breast cancer. We conducted a phase II trial of pembrolizumab monotherapy following induction chemotherapy to determine the efficacy of maintenance immunotherapy in patients with metastatic HER2-negative inflammatory breast cancer (IBC) and non-IBC triple-negative breast cancer (TNBC) and a biomarker study. Patients and Methods: Patients with a complete response, partial response, or stable disease (SD) after at least three cycles of chemotherapy for HER2-negative breast cancer received pembrolizumab, regardless of programmed death-ligand 1 expression. Pembrolizumab (200 mg) was administered every 3 weeks until disease progression, intolerable toxicity, or 2 years of pembrolizumab exposure. The endpoints included the 4-month disease control rate (DCR), progression-free survival (PFS), overall survival, and response biomarkers in the blood. Results: Of 43 treated patients, 11 had metastatic IBC and 32 non-IBC TNBC. The 4-month DCR was 58.1% [95% confidence interval (CI), 43.4–72.9]. For all patients, the median PFS was 4.8 months (95% CI, 3.0–7.1 months). The toxicity profile was similar to the previous pembrolizumab monotherapy study. Patients with high T-cell clonality at baseline had a longer PFS with pembrolizumab treatment than did those with low T-cell clonality (10.4 vs. 3.6 months, P = 0.04). Patients who achieved SD also demonstrated a significant increase in T-cell clonality during therapy compared with those who did not achieve SD (20% vs. 5.9% mean increase, respectively; P = 0.04). Conclusions: Pembrolizumab monotherapy achieved durable treatment responses. Patients with a high baseline T-cell clonality had prolonged disease control with pembrolizumab.

Year:

2024

Purpose: Accumulating toxicities hinder indefinite chemotherapy for many patients with metastatic/recurrent HER2-negative breast cancer. We conducted a phase II trial of pembrolizumab monotherapy following induction chemotherapy to determine the efficacy of maintenance immunotherapy in patients with metastatic HER2-negative inflammatory breast cancer (IBC) and non-IBC triple-negative breast cancer (TNBC) and a biomarker study. Patients and Methods: Patients with a complete response, partial response, or stable disease (SD) after at least three cycles of chemotherapy for HER2-negative breast cancer received pembrolizumab, regardless of programmed death-ligand 1 expression. Pembrolizumab (200 mg) was administered every 3 weeks until disease progression, intolerable toxicity, or 2 years of pembrolizumab exposure. The endpoints included the 4-month disease control rate (DCR), progression-free survival (PFS), overall survival, and response biomarkers in the blood. Results: Of 43 treated patients, 11 had metastatic IBC and 32 non-IBC TNBC. The 4-month DCR was 58.1% [95% confidence interval (CI), 43.4–72.9]. For all patients, the median PFS was 4.8 months (95% CI, 3.0–7.1 months). The toxicity profile was similar to the previous pembrolizumab monotherapy study. Patients with high T-cell clonality at baseline had a longer PFS with pembrolizumab treatment than did those with low T-cell clonality (10.4 vs. 3.6 months, P = 0.04). Patients who achieved SD also demonstrated a significant increase in T-cell clonality during therapy compared with those who did not achieve SD (20% vs. 5.9% mean increase, respectively; P = 0.04). Conclusions: Pembrolizumab monotherapy achieved durable treatment responses. Patients with a high baseline T-cell clonality had prolonged disease control with pembrolizumab.

Year:

2024

Collaborators (7)

Naoto Ueno

Professor of Medicine

University of Hawai'i Cancer Center

UNITED STATES
View details

Xiaoping Wang

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Yu Shen

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Toshiaki Iwase

Assistant professor, Investigator-Initiated Early Phase Clinical Trial Development and Regulatory Director

University of Hawai'i Cancer Center

UNITED STATES
View details

Bora Lim

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Alexandre Reuben

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Evan Cohen

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details